Hamza Zeinab S, Hozzein Wael N, El-Adl Khaled, Okla Mohammad K, AbdElgayed Gehad, Fadaly Wael A A, Mohamed Hussein S
Chemistry of Medicinal and Aromatic Plants Department, Research Institute of Medicinal and Aromatic Plants (RIMAB), Beni-Suef University Beni-Suef 62511 Egypt
Botany and Microbiology Department, Faculty of Science, Beni-Suef University Beni-Suef Egypt.
RSC Adv. 2025 Apr 25;15(17):13199-13213. doi: 10.1039/d5ra00484e. eCollection 2025 Apr 22.
Breast cancer and lung cancer are two of the most prevalent and deadly malignancies worldwide. Both cancers present significant challenges in terms of effective treatment and management, highlighting the urgent need for novel therapeutic strategies that can improve patient outcomes. This study focuses on the synthesis of novel heterocyclic compounds derived from the naturally formed camphor, aimed at evaluating their cytotoxicity. The research addresses the need for effective cancer treatments by presenting compounds that demonstrate significant inhibitory effects against MCF-7 breast carcinoma cells. Among these, compound 20 exhibited remarkable potency, with an IC value of 0.78 μM, surpassing the efficacy of standard chemotherapeutics, dasatinib (IC = 7.99 μM) and doxorubicin (IC = 3.10 μM). In the context of A549 lung cancer cells, compound 20 also showed strong inhibitory activity (IC = 1.69 μM), again outperforming dasatinib (IC = 11.8 μM) and doxorubicin (IC = 2.43 μM). To further elucidate the biological activities of these compounds, molecular docking studies were performed, revealing that compound 20 exhibited the highest binding energy among the tested compounds, supporting the experimental findings. These results indicate that the synthesized camphor-derived heterocycles, particularly compound 20, have significant potential as potent anticancer agents against breast and lung cancer cell lines.
乳腺癌和肺癌是全球最常见且致命的两种恶性肿瘤。这两种癌症在有效治疗和管理方面都面临重大挑战，凸显了对能改善患者预后的新型治疗策略的迫切需求。本研究聚焦于合成源自天然樟脑的新型杂环化合物，旨在评估其细胞毒性。该研究通过展示对MCF - 7乳腺癌细胞具有显著抑制作用的化合物，满足了有效癌症治疗的需求。其中，化合物20表现出显著的效力，IC值为0.78 μM，超过了标准化疗药物达沙替尼（IC = 7.99 μM）和阿霉素（IC = 3.10 μM）的疗效。在A549肺癌细胞的背景下，化合物20也显示出强大的抑制活性（IC = 1.69 μM），同样优于达沙替尼（IC = 11.8 μM）和阿霉素（IC = 2.43 μM）。为进一步阐明这些化合物的生物活性，进行了分子对接研究，结果显示化合物20在测试化合物中具有最高的结合能，支持了实验结果。这些结果表明，合成的樟脑衍生杂环化合物，特别是化合物20，作为针对乳腺癌和肺癌细胞系的强效抗癌剂具有巨大潜力。
